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Macrophage migration inhibitory factor (MIF) exerts multiple effects on immune cells, as well
as having functions outside the immune system. MIF can promote inﬂammation through the
induction of other cytokines, including TNF, IL-6, and IL-1 family cytokines. Here, we show
that inhibition of MIF regulates the release of IL-1α, IL-1β, and IL-18, not by affecting tran-
scription or translation of these cytokines, but via activation of the NLRP3 inﬂammasome.
MIF is required for the interaction between NLRP3 and the intermediate ﬁlament protein
vimentin, which is critical for NLRP3 activation. Further, we demonstrate that MIF interacts
with NLRP3, indicating a role for MIF in inﬂammasome activation independent of its role as a
cytokine. These data advance our understanding of how MIF regulates inﬂammation and
identify it as a factor critical for NLRP3 inﬂammasome activation.
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Macrophage migration inhibitory factor (MIF) is a plur-ipotent protein with a broad range of immunomodu-latory functions. It is produced and stored within
cytoplasmic vesicles in many cell types including macrophages,
T cells, and dendritic cells, enabling rapid release in response to a
range of stimuli1. MIF has topological homology to three bacterial
enzymes, oxalocrotonate tautomerase, 5-carboxymethyl-2-
hydroxymuconate isomerase, and chorismate mutase2–6, and
has an enzymatic activity as a D-dopachrome tautomerase, phe-
nylpyruvate tautomerase, and a thiol-protein oxidoreductase2,7,8.
However, the relationship between the catalytic activity and the
biological functions of MIF is unclear. MIF is an important reg-
ulator of protective responses to intracellular pathogens, includ-
ing Gram-negative bacteria, fungal pathogens, viruses, and
protozoa9–12. However, MIF is also linked to the pathogenesis of
inﬂammatory and autoimmune disorders, including sepsis,
rheumatoid arthritis, and systemic lupus erythematosus13,14.
Amongst its many effects on immune cell function, MIF has been
shown to modulate the production and secretion of proin-
ﬂammatory cytokines, including tumor necrosis factor (TNF),
interleukin-6 (IL-6), interferon-γ, and interleukin-1β (IL-1β)1,13.
In particular, MIF can regulate TNF and IL-6 through effects on
the expression of Toll-like receptor 4 (TLR4), p53, ERK, mitogen-
activated protein kinase (MAPK), c-Jun-N-terminal kinase, p38,
and MAPK phosphatase-11,15; however, the molecular mechan-
isms by which MIF regulates the secretion of IL-1β are not well
understood.
IL-1α, IL-1β, and IL-18 have important functions in med-
iating innate and adaptive immunity. IL-1α and IL-1β bind the
same receptor, IL-1R1, and share similar proinﬂammatory
properties mainly through the induction of cyclooxygenase
type-2, type 2 phospholipase A, and inducible nitric oxide
synthase, leading to recruitment of myeloid cells, including
neutrophils, to sites of inﬂammation16. Moreover, in concert
with IL-23, IL-1α and IL-1β can drive the expression and
secretion of IL-17 and IL-22 from T-helper type 17 (Th17) and
γδ T cells17. Although structurally homologous to IL-1α and
IL-1β, IL-18 binds a different receptor and has distinct func-
tions. In particular, IL-18, in combination with IL-12, stimu-
lates Th1-mediated responses, including the secretion of
interferon-γ (IFN-γ) by T cells and natural killer cells18. Both
IL-1β and IL-18 are initially produced as biologically inactive
pro-forms that require cleavage into the mature cytokines.
Typically, this processing is mediated by caspase-1, which is
activated following the formation of an inﬂammasome.
Inﬂammasomes are multimeric scaffolding complexes that acti-
vate caspase-119. Several inﬂammasome complexes have been
identiﬁed, with most incorporating at least one adaptor protein
such as an AIM2-like receptor (ALR), pyrin protein, or a
nucleotide-binding domain, leucine-rich-repeat-containing protein
(NOD-like receptor, NLR), such as NLRP1, NLRC4, or NLRP319–
22. This ALR or NLR engages apoptosis-associated speck-like pro-
tein containing a caspase activation and recruitment domain (ASC),
which, in turn, recruits and activates caspase-1. Activation of the
NLRP3 inﬂammasome is a two-step process. First, a priming signal,
such as a TLR ligand, promotes transcription of pro-IL-1β and
NLRP3 via nuclear factor-κB (NF-κB)-mediated signaling23. A
second signal is then required for the formation of the NLRP3
inﬂammasome complex. Numerous stimuli induce NLRP3
inﬂammasome formation, including extracellular adenosine tri-
phosphate (ATP), pore-forming toxins such as nigericin24 and
particulates such as uric acid crystals, silica, and alum25–27, as well
as bacterial, protozoan, and viral pathogens28–30.
The molecular mechanisms involved in NLRP3 inﬂamma-
some assembly are incompletely understood, but studies have
demonstrated roles for NIMA-related kinase-7 (NEK7) and the
type III intermediate ﬁlament protein vimentin31–34. Both
proteins have been shown to interact with NLRP3, suggesting
direct roles in NLRP3 inﬂammasome assembly and/or signal-
ing. Although IL-1 family cytokines have important functions
in protective immunity to various pathogens, dysregulation of
these cytokines is also associated with pathology in a number of
diseases, including cryopyrin-associated periodic syndromes,
autoinﬂammatory syndromes, gout, type II diabetes, and some
cancers35. Thus, understanding how inﬂammasome activation
is regulated is critical for the development of better treatment
strategies. Signiﬁcantly, one study has demonstrated that MIF is
required for IL-1β release and neutrophil recruitment in a
mouse model of monosodium urate (MSU) crystal-induced
gout36, suggesting a possible function of MIF in the regulation
of IL-1 in the speciﬁc context of NLRP3 activation.
Here we describe a speciﬁc function of MIF as a regulator of
the NLRP3 inﬂammasome complex in macrophages. Inhibition
of MIF in macrophages and dendritic cells inhibits NLRP3-
dependent secretion of IL-1β and IL-18 in vitro and in vivo.
Moreover, we demonstrate that MIF is required for the
NLRP3–vimentin interaction and that MIF interacts with NLRP3.
Our data identify a function of MIF in regulating NLRP3
inﬂammasome assembly and activation.
Results
MIF is required for the release of IL-1 family cytokines. To
assess the effects of MIF on the release of IL-1 family cytokines,
bone marrow-derived macrophages (BMDM) were isolated from
both wild-type (WT) andMif−/−mice. Cells were then treated with
the TLR4 agonist lipopolysaccharide (LPS) alone or in combination
with the NLRP3 inﬂammasome activator nigericin. In both WT and
Mif−/− BMDM, IL-1α, IL-1β, and IL-18 were secreted in response
to LPS and nigericin only (Fig. 1a–c). However, secretion of both
cytokines was signiﬁcantly lower in Mif−/− cells (Fig. 1a, b).
Interestingly, secretion of TNF-α in response to LPS was unaffected
in Mif−/− BMDM (Supplementary Figure 1A), although IL-6
secretion was signiﬁcantly lower (Supplementary Figure 1B).
Similar effects on levels of IL-1α and IL-1β production fromMif−/−
bone marrow-derived dendritic cells (BMDCs) were observed fol-
lowing treatment with LPS and the NLRP3 activators nigericin or
ATP (Supplementary Figure 1C and 1D).
We generated and screened a library of small molecule MIF
antagonists, identifying COR123625 as a potent inhibitor of MIF
that binds the molecule with high afﬁnity (Supplementary Figure 2A
and Supplementary Table 1). Initial structural validation studies
conﬁrmed that COR123625 bound within the enzymatic tautomer-
ase site of MIF near the catalytic N-terminal proline-1 residue37
(Supplementary Figure 2B), inhibiting tautomerase activity in a
dose-dependent manner (Supplementary Figure 2C). We then
assessed the effects of COR123625 on secretion of IL-1 family
cytokines by macrophages. Consistent with our ﬁndings in Mif−/−
BMDM, pre-treatment of immortalized BMDM with COR123625
had similar signiﬁcant inhibitory effects on IL-1β secretion at
concentrations of 25, 50 and 100 µM following activation with LPS
and nigericin (Supplementary Figure 2D), but had no effect on
TNF-α secretion in response to LPS (Supplementary Figure 2E). In
primary WT BMDM COR123625 similarly inhibited the secretion
of IL-1α, IL-1β, and IL-18 in response to LPS and nigericin
(Fig. 1d–f), but had no effect on LPS-induced TNF-α secretion
(Supplementary Figure 3A). Interestingly, in contrast to Mif−/−
BMDM, COR123625 also had no effect on LPS-induced IL-
6 secretion (Supplementary Figure 3B), possibly suggesting
differences between chronic MIF deﬁciency versus acute MIF
inhibition on IL-6 release by macrophages. COR123625 also
inhibited IL-1β release in response to the TLR2 ligand Pam3CSK4
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with nigericin and the TLR7 ligand imiquimod with nigericin
(Supplementary Figure 4A and 4B). Moreover, the commercially
available MIF inhibitor 4-iodo-6-phenylpyrimidine (4-IPP) also
inhibited IL-1β release by BMDM in response to LPS and nigericin
(Supplementary Figure 4C). Similarly, 4-IPP and another MIF
inhibitor, (S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole
acetic acid (ISO-1), inhibited both IL-1α and IL-1β release by
human THP-1 monocytic cells in response to LPS and nigericin
(Supplementary Figure 4D and 4E).
As both MIF and NLRP3 have been implicated in the pathogenesis
of septic shock38–40, we next investigated the effects of COR123625
on serum IL-1β and IL-18 in a mouse model of LPS-induced
endotoxemia. Intraperitoneal injection of LPS resulted in signiﬁcantly
increased serum IL-1β and IL-18 compared to sham-treated mice,
but this was abrogated by pre-treatment with COR123625 (Fig. 1g,
h). In this in vivo setting, COR123625 also reduced serum IL-6
(Fig. 1i), possibly suggesting effects on cells other than macrophages,
different signaling pathways, or knock-on effects of IL-1 inhibition in
macrophages/DCs. However, LPS-induced elevation of serum IL-6
was not signiﬁcantly inhibited in Mif−/− mice (Supplementary
Figure 4F). Serum IL-1β, on the other hand, was signiﬁcantly lower in
Mif−/− mice, compared to WT mice (Supplementary Figure 4G).
Moreover, co-injection of COR123625 into the LPS-treated Mif−/−
mice had no further effect on levels of IL-6 or IL-1β (Supplementary
Figure 4F and 4G). These data demonstrate that inhibition or
deﬁciency of MIF preferentially inhibits IL-1 family cytokines both
in vitro and in vivo.
MIF is required for NLRP3-dependent IL-1β release. We next
looked at whether MIF is required for IL-1β release in response to
other inﬂammasome stimuli. Following priming of both WT and
Mif−/− BMDM with LPS, the AIM2 inﬂammasome was activated
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Fig. 1 MIF is required for the release of IL-1 family cytokines. Primary murine WT and Mif−/− BMDMs were left untreated (control), primed with LPS (10
ngml−1), or primed with LPS followed by nigericin (5 µM) treatment for 1 h. Levels of a IL-1α, b IL-1β, and c IL-18 in cell culture supernatants were assessed
by ELISA. Primary WT BMDMs were left untreated, primed with LPS alone (10 ngml−1), primed with LPS, and then treated with or without COR123625
(50 µM) for 2 h before the addition of nigericin (5 µM) for 1 h. Levels of d IL-1α, e IL-1β, and f IL-18 in cell culture supernatants were assessed by ELISA.
C57BL6/J mice were injected intraperitoneally with vehicle control (saline), LPS alone (2 mg kg−1) or COR123625 (20mg kg−1) in combination with LPS for
2 h. Serum levels of g IL-1β, h IL-18, and i IL-6 were measured by ELISA. Data are expressed as means ± SEM, n= 3–4 mice per group. *P < 0.05, ***P <
0.005, ****P < 0.001, one-way ANOVA with a correction provided by the Tukey's multiple comparisons test
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via transfection of poly (deoxyadenylic-deoxythymidylic) (poly(dA:
dT)) into cells. No difference was observed in AIM2-dependent IL-
1β release between WT and Mif−/− cells (Fig. 2a). Similarly, inhi-
bition of MIF with COR123625 had no effect on levels of secreted
IL-1β in response to poly(dA:dT) (Fig. 2b). Moreover, COR123625
had no effect on ﬂagellin-induced (NLRC4-dependent) IL-1β
release (Fig. 2c). In addition, IL-1α release was similarly unaf-
fected by COR123625 in these experiments (Supplementary Fig-
ure 5A–5C). These data suggest that the effects of MIF on IL-1
release may be speciﬁc to the NLRP3 inﬂammasome. To investigate
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this further, we tested the effects of COR123625 on IL-1β release by
BMDM in response to other known NLRP3 stimuli, including MSU
crystals26, silica25, and the inﬂuenza A peptide, PB1-F230. In each
case, pre-treatment of cells with COR123625 signiﬁcantly inhibited
the release of both IL-1β and IL-18 (Fig. 2d–i). Similarly, IL-1β
release by Mif−/− BMDM was signiﬁcantly lower in response to
MSU and silica compared to WT cells (Supplementary Figure 5D
and 5E).
To determine whether exogenous MIF could reconstitute NLRP3-
dependent IL-1β release, we treated both WT and Mif−/− BMDM
with recombinant murine MIF (rMIF) and stimulated the cells with
LPS and nigericin. While Mif−/− BMDM again demonstrated
impaired IL-1β release in response to LPS and nigericin, the addition
of rMIF had no effect on this (Fig. 2j). Moreover, while COR123625
inhibited NLRP3-dependent IL-1β release by WT BMDM, it had no
further effect on Mif−/− cells (Fig. 2j), conﬁrming that it does not
have MIF-independent effects on IL-1β release in this setting. To test
this further, we also stimulated Mif−/− cells with LPS and nigericin
after culturing the cells in MIF-containing conditioned medium
fromWT BMDM. This conditioned medium was taken from resting
WT cells and MIF concentration was measured at 2428 pgml−1 by
enzyme-linked immunosorbent assay (ELISA). Again, reconstituting
MIF this way had no effect on NLRP3-dependent IL-1 release
(Fig. 2k). Together, these data suggest that exogenous MIF does not
facilitate NLRP3 activation, but that MIF instead acts in a cell-
intrinsic, intracellular manner.
ISO-1 inhibits IL-1β in response to Plasmodium falciparum.
Studies have highlighted a role for NLRP3-dependent IL-1β release
in the immune response involved in the pathogenesis of
malaria28,29,41. Of particular relevance, IL-1 is thought to play a
pivotal role in low birth weight due to placental malaria42,43.
Moreover, placental malaria is also associated with increased pla-
cental MIF44. Thus, to test whether MIF inhibition might reduce IL-
1β release in the context of malaria, we treated peripheral blood
mononuclear cells (PBMCs) isolated from pregnant women in
Fig. 2MIF regulates NLRP3-dependent release of IL-1 family cytokines. a Primary murine WT orMif−/− BMDMs were left untreated, primed with LPS alone
(10 ngml−1), or primed with LPS before transfection of poly dA:dT (1 µgml−1) for 5 h. WT BMDMs were left untreated, primed with LPS (10 ngml−1), or
primed with LPS before the addition of COR123625 (50 µM) for 2 h before transfection of b poly dA:dT (1 µg ml−1) or c ﬂagellin (250 ngml−1) for 5 h.
Alternatively, following priming of WT BMDMs with LPS, cells were treated with d, g MSU (150 µg ml−1), e, h silica (150 µg ml−1), or (f, i) PBI-F2 peptide
(100 µg ml−1) for 6 h. Levels of a–f IL-1β and g–i IL-18 in cell culture supernatants were quantiﬁed by ELISA. j Primary WT or Mif−/− BMDMs were primed
with LPS (10 ngml−1) in the presence or absence of recombinant murine MIF (rMIF, 10 ngml−1) before stimulation with nigericin (5 µM) for 1 h. In addition,
cells were treated with or without COR123625. Levels of IL-1β in cell culture supernatants were assessed by ELISA. k Primary WT or Mif−/− BMDMs were
primed with LPS (10 ngml−1) in the presence or absence of MIF-containing conditioned media from WT BMDM before stimulation with nigericin (5 µM)
for 1 h. Levels of IL-1β in cell culture supernatants were assessed by ELISA. Data are expressed as means ± SEM, n= 3 mice. *P < 0.05, **P < 0.01, ***P <
0.005, ****P < 0.001, one-way ANOVA with a correction provided by the Tukey's multiple comparisons test
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Fig. 3 ISO-1 inhibits IL-1β in response to Plasmodium falciparum. a–c Viable human PBMCs collected from three donors were co-cultured with 2 × 106 non-
infected or CS2-infected RBC. Cells were either treated with DMSO alone (control) or with increasing concentrations of ISO-1 (5, 25, or 50 µM) for 16 h.
Levels of IL-1β in cell culture supernatants were quantiﬁed by ELISA. d Percentage inhibition calculated for all three donors ± SEM ***P < 0.005, ****P <
0.001, one-way ANOVA with a correction provided by the Tukey's multiple comparisons test
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malaria-endemic areas of Papua New Guinea with Plasmodium
falciparum CS2-infected red blood cells (CS2-RBC) ex vivo, in the
presence or absence of a MIF inhibitor. In three separate donors, we
found that ISO-1 signiﬁcantly inhibited CS2-RBC-induced IL-1β
release by PBMC (Fig. 3a–d). Importantly, ISO-1 did not affect
PBMC viability or phagocytic uptake of infected RBCs (Supple-
mentary Figure 6A and 6B). These data further suggest that IL-1β
release in response to P. falciparum is dependent on NLRP3 and
MIF.
MIF is required for NLRP3 inﬂammasome assembly. The fact
that inhibiting MIF speciﬁcally abrogates NLRP3-dependent IL-
1β and IL-18 release suggests that MIF is involved in NLRP3
inﬂammasome activation or assembly, rather than directly
inﬂuencing IL-1β production. To conﬁrm this, we ﬁrst investi-
gated if LPS-dependent NF-κB activation was affected by inhi-
bition of MIF, as it is required for the transcription of both IL-1β
and NLRP323. Murine macrophage RAW-ELAM cells, which
stably express the ELAM-NF-κB reporter construct, were treated
with LPS is the presence or absence of COR123625 or ISO-1.
Inhibition of MIF had no effect on NF-κB activation in these cells
(Fig. 4a). Next, we assessed Il1b mRNA expression in BMDM and
the human THP-1 monocytic cell line. In both cell types, MIF
inhibition did not inhibit LPS-induced expression of Il1b and, in
fact, signiﬁcantly increased LPS-induced Il1b expression in
BMDM (Fig. 4b, c).
Next, we tested whether inhibition of MIF affected translation
and processing of proteins pivotal for NLRP3 inﬂammasome
assembly and activation. MIF inhibition with COR123625 had no
effect on intracellular levels of pro-IL-1β, NLRP3, pro-caspase-1, or
ASC protein in LPS-treated BMDM (Fig. 4d, e). However,
COR123625 did inhibit the processing and release of both
caspase-1 and IL-1β (Fig. 4d). Similarly, levels of intracellular
pro-IL-1β in LPS-treated WT andMif−/− BMDM were comparable
(Supplementary Figure 7A and 7B). Moreover, COR inhibited IL-1β
processing regardless of whether it was added before or after
priming with LPS (Supplementary Figure 7C). Together, these data
demonstrate that blocking MIF speciﬁcally inhibits NLRP3
inﬂammasome-dependent processing of pro-IL-1β, rather than
LPS-dependent effects on protein expression.
Activation of the NLRP3 inﬂammasome is characterized by the
formation of an ASC “speck”; the result of oligomerization of
ASC molecules into a large protein complex45. Typically, in
macrophages, this is followed by caspase-1-dependent cell death,
or pyroptosis. To determine if MIF is required for inﬂammasome
assembly and activation, we next evaluated the effects of
COR123625 on NLRP3-mediated ASC-speck formation. In
response to priming with LPS and NLRP3 activation with
nigericin or silica, immortalized BMDM stably expressing
ﬂuorescent ASC-cerulean displayed signiﬁcant ASC-speck for-
mation over time, which was signiﬁcantly inhibited when cells
where treated with COR123625 (Fig. 5a–d and Supplementary
Figure 8A and 8B). To test whether MIF inhibition also inhibited
pyroptosis, we looked at cell death in BMDM following activation
of NLRP3 with nigericin using a lactate dehydrogenase (LDH)
release assay. As expected, treatment with LPS+ nigericin
signiﬁcantly increased pyroptosis, while treatment with
COR123625 abrogated this effect (Fig. 5e). Collectively, these
data demonstrate that MIF is speciﬁcally required for initiation
and assembly of the NLRP3 inﬂammasome upstream of ASC
oligomerization.
Intriguingly, cleavage of caspase-1 to the p20 form was either
no different, or higher in Mif−/− BMDM treated with LPS and
nigericin compared to WT controls, and the Mif−/− cells also
showed higher basal levels of pro-caspase-1 (Fig. 5f), potentially
suggesting a role for MIF in caspase-1 expression and/or
degradation. Intracellular levels of pro-IL-1β (Supplementary
Figure 7A and 7B) were comparable in WT and Mif−/− cells.
Nonetheless, processing and release of IL-1β was still reduced
compared to WT controls (Fig. 5f) and ASC-speck formation was
reduced in Mif−/− BMDM (Fig. 5g, h). Thus, these data further
conﬁrm a role for MIF in ASC-speck/inﬂammasome formation.
MIF mediates interactions between vimentin and NLRP3. A
recent study has demonstrated that activation and assembly of the
NLRP3 inﬂammasome is dependent on interaction between
NLRP3 and the intermediate ﬁlament protein vimentin31. In
agreement with this, we found that treatment of macrophages
with the vimentin-binding anti-angiogenic compound withaferin
A abrogated ASC-speck formation in macrophages (Supple-
mentary Figure 8C and 8D), while super-resolution microscopy
revealed NLRP3 staining on vimentin-positive intermediate ﬁla-
ments in BMDM treated with LPS and nigericin (Supplementary
Figure 8E). Thus, we hypothesized that MIF might be involved in
mediating the NLRP3–vimentin interaction. To test this, we ﬁrst
performed co-immunoprecipitation (co-IP) experiments in WT
and Mif −/− BMDM. In WT BMDM, vimentin could be detected
in all samples following immunoprecipitation with NLRP3 and
this interaction increased with LPS and nigericin (Fig. 6a). In Mif
−/− BMDM, this interaction was greatly reduced (Fig. 6a).
However, because vimentin, which is a common contaminant in
afﬁnity puriﬁcation mass spectrometry (Crapome.org, 2013; http://
www.crapome.org/46), was also observed in immunoglobulin G
(IgG) control samples, we sought to conﬁrm these results using
ﬂuorescence lifetime imaging microscopy-ﬂuorescent resonance
energy transfer (FLIM-FRET), which only occurs when molecules
are in close proximity (2–10 nm)47. In agreement with our co-IP
data, increased FRET occurred between NLRP3 and vimentin in
BMDM treated with LPS followed by nigericin, indicating increased
interaction between the two molecules (Fig. 6b–d and Supplemen-
tary Figure 8F). This interaction was signiﬁcantly reduced in the
presence of COR123625 (Fig. 6b–d and Supplementary Figure 8F).
Taken together, our data suggest that MIF is required for the
interaction between NLRP3 and vimentin, which is in turn required
for NLRP3 inﬂammasome assembly.
MIF interacts with NLRP3. Our data suggest a critical role for
MIF in assembly of the NLRP3 inﬂammasome, facilitating
interactions between NLRP3 and vimentin/intermediate ﬁla-
ments. Thus, we next looked to see whether MIF interacts with
the NLRP3 inﬂammasome. Confocal analysis of MIF staining in
ASC-cerulean immortalized BMDM (iBMDM) revealed co-
localization of MIF and ASC on the ASC-speck (Fig. 7a). This
was evident at early time points (5–20 min), but not later (30 min
+), suggesting a role for MIF early in inﬂammasome assembly.
Similarly, MIF could be seen to co-localize with NLRP3 after
treatment of LPS-primed BMDM with nigericin (Fig. 7b). After
20 min, NLRP3 and MIF could be seen in large structures, similar
to ASC specks. However, these structures were not evident in cells
treated with nigericin and COR123625 (Fig. 7b).
We next sought to determine whether MIF interacts with
NLRP3. Co-IP of iBMDM lysates, following treatment of LPS-
primed cells with nigericin ± COR123625, using both MIF and
NLRP3 antibodies, revealed direct interactions between MIF and
NLRP3, as well as conﬁrming the NLRP3–vimentin interaction
(Fig. 8a). Similar to ﬁndings with vimentin and NLRP3, the
interaction between MIF-NLRP3 was reduced in cells treated with
COR12365. To test this further, we used FLIM-FRET analysis,
which showed increased FRET between MIF and NLRP3 in
BMDM treated with LPS and nigericin (Fig. 8b). However, pre-
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Fig. 4 Inhibition of MIF does not prevent transcription or translation of IL-1β. a NF-κB luciferase activity measured in RAW-ELAM macrophages pre-treated
with COR123625 (50 µM) for 1 h prior to priming with LPS (100 ngml−1) for 4 h. b Primary murine WT BMDM or c human undifferentiated THP-1 cells
were left untreated, primed with LPS (100 ngml−1) alone for 4 h, or pre-treated with COR123625 (50 µM) for 1 h before the addition of LPS. Relative
expression (RE—relative to 18S) of il1b mRNA was quantiﬁed using real-time PCR. Data are mean ± SEM, n= 3 independent experiments. *P < 0.05, ****P <
0.001, one-way ANOVA with a correction provided by the Tukey's multiple comparisons test. d WT BMDMs were left untreated, primed with LPS alone
(100 ngml−1) for 5 h, pre-treated with COR123625 for 1 h prior to the addition of LPS, primed with LPS before inﬂammasome activation with nigericin (5
µM) for 1 h, or treated with COR123625 before LPS and nigericin stimulation. Western blot analysis of cellular supernatants and lysates to assess levels of
NLRP3, ASC, pro-IL-1β, pro-caspase-1, mature IL-1β (p17), caspase-1 (p20), and β-actin was performed. e Densitometry was used to calculate expression of
intracellular proteins shown in d. Mean expression was normalized to β-actin and expressed as relative to levels in control (untreated) samples n=
4 separate experiments (four mice)
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Fig. 5 Inhibition of MIF prevents NLRP3 inﬂammasome activation. ASC-cerulean macrophages were primed with LPS (10 ngml−1) overnight. The following
day cells were treated with COR123625 (50 µM) for 2 h before activation of the inﬂammasome with a nigericin (10 µM) (1 h) or b silica (150 µgml−1) (4 h).
Confocal images are representative of three independent experiments. c, d Data are presented as the percentage of ASC-speck-positive cells. Data shown
are mean ± SEM of three independent experiments. e WT BMDMs were left untreated, treated with LPS alone (100 ngml−1) for 5 h, treated with
COR123625 for 1 h prior to the addition of LPS, primed with LPS before inﬂammasome activation with nigericin (5 µM) for 1 h, or treated with COR123625
before LPS and nigericin stimulation. Levels of LDH release were quantiﬁed using the Promega cytotoxicity assay. f WT or Mif−/− BMDMs were treated
with LPS (10 ngml−1)+ nigericin (5 μM) and lysates and supernatants analyzed by Western blot for caspase-1 and IL-1β. Images are representative of >3
mice. g BMDMs from WT and Mif−/− mice were treated with (10 ngml−1)+ nigericin (5 μM), ﬁxed and stained for ASC, and analyzed by confocal
microscopy. Images are z projections of multiple z-stacks. h Quantitation of ASC specks in g, n= 3 mice per group. Data are expressed as percentage
increase of mean ± SEM from three mice. *P < 0.05, **P < 0.01, ***P < 0.005, or ****P < 0.001, one-way ANOVA with a correction provided by the Tukey's
multiple comparisons test
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treatment of the cells with COR123625 signiﬁcantly inhibited
this interaction (Fig. 8b). These data demonstrate, for the ﬁrst
time, that MIF interacts with NLRP3 and suggests that this
interaction may be important for the interaction between NLRP3
and vimentin, which is required for assembly of the
inﬂammasome.
Discussion
MIF was one of the ﬁrst cytokines identiﬁed and has been shown
to have multiple roles in the immune system. In particular, it has
a protective effect against a number of intracellular pathogens,
but a pathological role in inﬂammatory and autoimmune dis-
eases14. A likely common factor in both of these is the regulation
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Fig. 6MIF is required for interactions between NLRP3 and vimentin. a Primary murine WT and Mif−/− BMDMs were left untreated, primed with LPS alone
(100 ngml−1) for 5 h, or primed with LPS before inﬂammasome activation with nigericin (5 µM) for indicated times. Lysates were immunoprecipitated with
anti-NLRP3 antibody, followed by Western blot analysis with anti-vimentin antibody. b WT BMDMs were primed with LPS alone (100 ngml−1) for 5 h,
primed with LPS followed by nigericin (5 µM) for 1 h, or primed with LPS followed by COR123625 (50 µM) for 2 h prior to nigericin (5 µM) treatment for 30
min. Levels of interaction between NLRP3 and vimentin were assessed by FLIM-FRET. FLIM-FRET images presented are representative of three
independent experiments (three mice). Scale bar= 50 μm. c Changes in the amplitude-weighted average lifetime (τ Av Amp) of the donor (A488) due to
proximity to the acceptor (A568). Representative graph from one mouse (nine separate ﬁelds per mouse). ****P < 0.001, one-way ANOVA with a
correction provided by the Tukey's multiple comparisons test. d Combined data from three mice, analyzed by paired t test. *P < 0.05
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of other cytokines, increasing the expression and secretion of
proinﬂammatory cytokines, while inhibiting anti-inﬂammatory
molecules such as IL-1038,48. In addition, MIF has been shown to
counteract the immunoregulatory effects of glucocorticoids (GCs)
49,50, making it an attractive therapeutic target, with the potential
to both directly modify inﬂammation and improve sensitivity to
GCs. Here, we have uncovered a previously unrecognized and
highly speciﬁc role for MIF in the activation of the NLRP3
inﬂammasome and subsequent processing and release of the IL-1
family cytokines IL-1α, IL-1β, and IL-18. Previous work has
demonstrated that loss of MIF can inhibit the LPS-induced
release of TNF-α by downregulating TLR4 expression51.
Although we did not look at TLR4 expression here, we saw no
effect of MIF inhibitors on TLR4-induced NF-κB activation and
intracellular levels of pro-IL-1β were not affected by loss or
inhibition of MIF. Moreover, similar effects of MIF inhibition on
IL-1 release were seen when other TLR ligands were used.
Interestingly, inhibition of MIF with COR123625 actually
increased expression of Il1b mRNA. The reason for this is not
clear, although previous studies have demonstrated similar dis-
sociation between il1b mRNA and intracellular levels of pro-
tein52,53. It may be that mRNA stability is changed in COR-
treated cells, or that post-translational regulation of pro-IL-1β is
somehow altered (i.e., increased degradation). Given that loss of
MIF blocks inﬂammasome activation and processing of pro-IL-
1β, it may be that cells engage compensatory mechanisms to
ASC
5 min
10 min
30 min
LPS + nigericin NLRP3 MIF
MIF
a
b
Fig. 7 MIF co-localizes with the NLRP3 inﬂammasome. a ASC-cerulean macrophages were primed with LPS (10 ngml−1) overnight. The following day cells
were treated with nigericin (10 µM) for the indicated times. Co-localization of ASC (green) and MIF (red) were visualized using confocal microscopy.
Confocal images are representative of at least three independent experiments. b Primary murine BMDMs were treated with LPS (10 ngml−1) overnight,
and then treated with or without COR123625 (50 µM), followed by nigericin (5 µM) for 20min. Cells were ﬁxed and stained with antibodies against NLRP3
and MIF. Nuclei were stained with DAPI. All scale bars= 10 μm
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increase IL-1β transcription, but why this does not equate to
greater levels of protein is not clear.
The NLRP3 inﬂammasome has important roles to play in
immune responses to multiple endogenous and exogenous
insults, including MSU crystals, mitochondrial products, intra-
cellular pathogens, and particulate material, such as silica and
asbestos62. While much is known about stimuli that trigger
NLRP3 activation, the process by which it is activated and
assembled are less well understood. However, a recent study
demonstrated a key role for the intermediate ﬁlament protein
vimentin, which interacts with NLRP3 upon stimulation of cells
with LPS and ATP, potentially providing a scaffold for sub-
sequent activation and/or assembly31. Here, we demonstrate not
only a novel role for MIF in regulating the NLRP3–vimentin
interaction following activation but also that MIF itself interacts
with NLRP3. Moreover, the dynamics of this interaction mirror
those of NLRP3–vimentin, increasing after inﬂammasome acti-
vation and inhibited by blocking MIF. Precisely how MIF reg-
ulates NLRP3 activation is unclear at this stage. However, a
number of studies have demonstrated that MIF has chaperone-
like activity with model proteins63. More recently, a study has
shown MIF to act as an ATP-independent protein folding cha-
perone, preventing misfolding of mutant superoxide dismutase64,
the accumulation of which accompanies development of the
neurodegenerative disease amyotrophic lateral sclerosis (ALS).
Thus, it is possible that MIF might act as a chaperone for NLRP3,
perhaps stabilizing the protein and/or promoting its interaction
with vimentin. Further studies, beyond the scope of this paper,
are required to uncover the precise mechanism through which
MIF facilitates NLRP3 activation and assembly and how it binds
NLRP3. Moreover, further studies to determine whether MIF also
regulates NLRP3 oligomerization or the interactions between
NLRP3 and ASC or NLRP3 and NEK732–34 would be of con-
siderable interest. Importantly, however, our data suggest that this
role of MIF is independent of its role as a cytokine, as recombi-
nant and native MIF were unable to recover NLRP3-dependent
IL-1 release in Mif−/− macrophages.
While inﬂammasome activation and caspase-1 are not exclu-
sively required for the processing and release of IL-1α, NLRP3-
activating stimuli are known to induce IL-1α release. In some
cases, this may be the result of passive release from dying
cells55,56, but in others may be mediated via a caspase-1-
dependent mechanism, albeit one that is independent of caspase-
1 catalytic activity56. Correspondingly, our data demonstrate that
loss or inhibition of MIF signiﬁcantly inhibits IL-1α release in
response to NLRP3-activating stimuli. Moreover, as with IL-1β,
IL-1α release was not inhibited by MIF depletion or inhibition in
response to the AIM2 and NLRC4 activators poly(dA:dT) and
ﬂagellin, respectively, suggesting that the inhibitory effects on IL-
1α are NLRP3-dependent.
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Fig. 8 MIF interacts with NLRP3. a Immortalized BMDMs were left untreated, primed with LPS alone (100 ngml−1) for 5 h, or primed with LPS before
inﬂammasome activation with nigericin (5 µM, 30min). Lysates were immunoprecipitated with anti-MIF or anti-NLRP3 antibody, followed by western blot
analysis with antibodies against NLRP3 and MIF. b WT BMDMs were primed with LPS alone (10 ngml−1) for 5 h, primed with LPS followed by NLRP3
activation with nigericin (5 µM) for 30min, or primed with LPS followed by COR123625 (50 µM) treatment for 2 h prior to the addition of nigericin (5 µM)
for 30min. Levels of interaction between MIF and NLRP3 were assessed by FLIM-FRET microscopy. FLIM-FRET images presented are representative of
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Intriguingly, our data suggest differences between acute inhi-
bition of MIF with antagonists versus chronic MIF deﬁciency
with respect to caspase-1. In particular, while the MIF inhibitor
COR123625 clearly inhibited caspase-1 cleavage in macrophages,
Mif−/− BMDM showed no discernable difference in caspase-1
p20 following treatment with the NLRP3 activator nigericin.
Nonetheless, IL-1β processing and release was still inhibited in
Mif−/− BMDM, possibly suggesting that the caspase-1 is either
not activated, as has recently been suggested for p2054, or is
unable to cleave IL-1β in these cells. Moreover, our data
demonstrate that ASC-speck formation is also inhibited in
Mif−/− BMDM, further indicating that MIF is required for
activation/assembly of the NLRP3 inﬂammasome.
Despite this difference with regard to caspase-1 p20, our data
demonstrate that levels of pro-IL-1β are comparable in Mif−/−
and WT BMDM and that it is speciﬁcally NLRP3-dependent IL-
1β release that is inhibited in Mif−/− cells, suggesting that
upstream effects on LPS signaling or downstream effects on IL-1β
release are less likely to be responsible for the effects in Mif−/−
cells. However, we cannot rule out the possibility that other, as yet
undiscovered, effects of MIF depletion are simultaneously at play,
potentially including effects on secretion/release. Importantly,
COR123625 had no further effect on IL-1 release by Mif−/− cells
either in vitro or in vivo, so it is unlikely that the inhibitor reg-
ulates NLRP3 in an MIF-independent manner. The increase in
basal levels of pro-caspase-1 in Mif−/− BMDM could suggest a
role for MIF in regulating production and/or degradation of the
protein, or may be indicative of compensatory mechanisms at
play in the knockout cells. Alternatively, as opposed to differences
between chronic and acute loss of MIF, these results might
instead suggest that MIF inhibitors that target the catalytic pocket
of MIF (e.g., COR123625, ISO-1, 4-IPP) do not target other
effects of MIF on IL-1 release pathways. However, further work is
needed to fully understand the role of MIF in caspase-1 expres-
sion and activation, as well as the differences between MIF
knockout and MIF antagonists with respect to caspase-1
activation.
Our data indicate a role for MIF in regulating IL-1β in human
PBMCs in response to P. falciparum-infected erythrocytes. Pre-
vious studies have highlighted a role for IL-1β release in both
protective and pathogenic responses to malaria28,29,41,57,58. In
particular, IL-1 is thought to play a pivotal role in low birth
weight due to placental malaria as it can decrease the activity of
system A amino acid transporters in vitro and because placental
IL-1 levels are negatively associated with birth weight in women
suffering placental malaria with intervillositis42,43. Moreover,
Plasmodium-induced IL-1β release has been shown to be
dependent on both NLRP3 and AIM228,29,41. Given the speciﬁcity
for NLRP3 demonstrated here, our data suggest that, ex vivo, IL-
1β release by PBMCs in response to P. falciparum infection is
largely, if not entirely, NLRP3-dependent. Studies have also
shown that MIF is increased in the placenta of malaria-infected
women and is thought to be produced by leukocytes in the
intervillous space44,59. Whether this increase in MIF is directly
related to the increase in IL-1β is not clear and warrants further
investigation. Interestingly P. falciparum produces a MIF
homolog which can bind the MIF receptor CD7460 and circu-
lating levels of this Plasmodium-derived MIF (pMIF) are asso-
ciated with parasitemia and a greater proinﬂammatory state in
the host60,61. The precise role of this parasite-derived MIF is
unclear, although in a mouse model it was shown to induce
proinﬂammatory responses and dampen memory T cell respon-
ses by increasing terminal differentiation, which increases sus-
ceptibility to apoptosis, potentially reducing protection against
subsequent infection60. Whether pMIF can regulate NLRP3-
dependent responses remains to be seen, although our data with
native and recombinant MIF would suggest that exogenous MIF
does not act on NLRP3 inﬂammasome activation.
An intriguing question that arises from our ﬁndings is how
much this role in NLRP3 activation accounts for other known
effects of MIF in the immune system. A recent study has
demonstrated that MIF is required for IL-1β production and
neutrophil accumulation in the joints of mice injected with MSU
in a model of gout36. Our data provide a direct mechanism for
this observation, particularly given that gout is an NLRP3-
dependent pathology. Similarly, both MIF and NLRP3 have been
shown to have pathological roles to play in mouse models of
septic shock38–40 and our ﬁndings suggest these effects may be
interdependent. Moreover, other known effects of MIF may also
be NLRP3-dependent, such as the reported protective roles for
MIF in many microbial infections. For example, both MIF and
NLRP3 have been shown to have a protective role in host
immune responses to the fungal pathogen Aspergillus fumiga-
tus12,65. Finally, a recent study has also suggested that NLRP3
upregulation is linked to GC resistance in leukemia cells66,
potentially indicating that MIF effects on NLRP3 activation might
be behind its negative effects on GC sensitivity. Further work
focusing on the role of this MIF–NLRP3 interaction in other
known effects of MIF, including macrophage motility and
recruitment and counteraction of GC activity, would be of con-
siderable interest, both for our understanding of the biology of
this molecule and for the development of future therapeutic
strategies.
In summary, our data highlight a previously unrecognized role
for MIF in NLRP3 inﬂammasome-dependent processing and
release of IL-1 family cytokines. Depletion or inhibition of MIF in
macrophages and dendritic cells resulted in the inhibition of IL-
1α, IL-1β and IL-18 in response to NLRP3-activating stimuli. We
demonstrate that loss of MIF does not alter the production of IL-
1, but instead MIF is required for NLRP3–vimentin interactions,
which are crucial for assembly of the inﬂammasome. Moreover,
MIF interacts with NLRP3, potentially suggesting that MIF is
directly involved in assembly and activation of the NLRP3
inﬂammasome.
Methods
Animals. Eight-week-old male C57BL/6 mice (WT) and Mif−/− (on a C57BL/6
background)67 mice were used with the approval of the appropriate Monash
University Ethics Committee (MMCB) and in accordance with National and
institutional guidelines. The Mif−/− mice were originally obtained from Professor
R. Bucala, Yale School of Medicine. All animals were housed in individually ven-
tilated cages, used at 8–12 weeks and culled using CO2 asphyxiation.
Cell culture. Bone marrow cells were collected from femurs of WT and Mif−/−
mice and differentiated for 7 days in RPMI 1640 (Thermo Fisher Scientiﬁc) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS) (JRH Biosciences,
Victoria, Australia), 2 mM L-glutamine, 1% penicillin/streptomycin (Complete
RPMI) and with 15% L929 conditioned medium. Differentiated BMDMs were
plated on day 7 for treatment the following day. For BMDCs, bone marrow cells
were differentiated for 11 days in complete RPMI with 10%
granulocyte–macrophage colony-stimulating factor conditioned medium (Ag8653
myeloma cells). Differentiated primary BMDCs were plated on day 11 for treat-
ment the following day. iBMDMs and ASC-cerulean-iBMDM were grown in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% FCS and 2mM
glutamine. The human monocytic THP-1 cell line was cultured in complete RPMI.
RAW264.7 mouse macrophage cells stably expressing the NF-κB-dependent
ELAM-luciferase reporter construct were cultured in complete RPMI with 0.5 mg
ml−1 G418. Cells were maintained at 37 °C in a humidiﬁed atmosphere of 5% CO2.
Collection of PBMC. PBMCs, isolated from venous blood of three pregnant
women at ﬁrst antenatal visit, were collected in 2007 at Alexishafen Health Centre,
Madang, Papua New Guinea, following written, informed consent. PBMCs were
stored in liquid nitrogen until analysis. Viability and number of thawed PBMCs
was assessed by trypan blue staining. Ethics approval was granted for this work by
the Medical Research Advisory Council of PNG (05/08) and by the Melbourne
Health Human Research Ethics Committee (2001.018.).
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In vivo LPS challenge. Mice were injected intraperitoneally with 20 mg kg−1
COR123625 or vehicle control (saline) in combination with 2 mg kg−1 LPS or
phosphate-buffered saline (PBS). After 2 h mice were killed, and serum levels of IL-
1β, IL-18, and IL-6 were measured by ELISA.
Inﬂammasome activation. BMDM, iBMDM (5 × 105 cells ml−1), and THP-1 cells
(1 × 106 cells ml−1) were plated in 96-well plates for cytokine and LDH quantiﬁ-
cation. The following day WT BMDMs were treated with 10 or 100 ng ml−1 LPS,
10 µg ml−1 imiquimod, or 10 ng ml−1 Pam3CSK4 (all from Sigma) for 3–5 h or
overnight. COR123625 (25–100 μM), ISO-1 (Abcam) (25–100 μM), and 4-IPP
(Sigma) (50 µM) were added to cells either 1 h prior to LPS or 2 h prior to
inﬂammasome activation. Cells were then stimulated with inﬂammasome activa-
tors: nigericin (Cayman Chemical) (5 or 10 µM for 5–60 min), adenosine 5′-tri-
phosphate disodium salt (ATP, Sigma) (5 or 10 mM for 1 h), silica (Invivogen)
(150 µg ml−1 for 1–6 h), MSU (Invivogen) (150 µg ml−1 for 6 h), PBI-F2 peptide
(provided by A. Mansell) (100 μg ml−1 for 6 h). Poly(dA:dT) (Sigma) (1 µg ml−1
for 5 h) or ﬂagellin (Sigma) (250 ng ml−1 for 5 h) were transfected into cells with
Lipofectamine 2000® reagent (Thermo Fisher Scientiﬁc). Supernatants were
removed and analyzed using ELISA Kits according to the manufacturer’s
instructions (BioLegend). LDH release was measured using the CytoTox96® non-
radioactive cytotoxicity assay (Promega).
Infection of PBMC with P. falciparum-infected erythrocytes. Type O ery-
throcytes (Australian Red Cross Blood Service) infected with P. falciparum strain
CS2, which expresses the gene (var2csa) and phenotype (chondroitin sulfate-A
binding) of parasites associated with placental malaria68, were cultured in RPMI-
HEPES supplemented with 0.2% NaHCO3, 0.5% albumax II (Gibco), and 5% heat-
inactivated pooled human serum (Australian Red Cross Blood Service) at 37 °C in a
low oxygen environment (1% O2, 5% CO2, 94% N2). Trophozoite stage infected
erythrocytes were puriﬁed by Percoll gradient centrifugation prior to use as stimuli
in the experiment. Non-infected RBCs (from the same donor as used for parasite
culture) were used as a control.
A total of 2 × 105 viable PBMCs were co-cultured with 2 × 106 infected RBCs or
non-infected RBC control/well (ratio 1:10) in complete RPMI with varying
concentrations of ISO-1 or DMSO control for 16 h at 37 °C at 5% CO2. Levels of
IL-1β in cell culture supernatants were quantiﬁed using the human IL-1β ELISA
Development Kit (MabTECH). Remaining cells in the wells were re-suspended in
5 μl of PBS, pipetted onto glass slides, then stained using Diff-Quik® (Baxter,
Australia), and ﬁnally investigated by light microscopy to conﬁrm phagocytosis of
parasite by white blood cells.
RNA isolation and quantitative real-time PCR. BMDM or THP-1 cells were
treated with LPS (100 ng ml−1) for 4 h with or without COR123625 (50 μM). Total
RNA was extracted using chloroform/isopropanol precipitation and com-
plementary DNA (cDNA) was prepared from 0.5 µg of total RNA according to the
M-MLV reverse transcription protocol using the Tetro cDNA Synthesis Kit (Bio-
line, Australia). Quantitative real-time PCR analyses were performed on duplicate
samples using the Applied Biosystems Power SYBR Green PCR Master Mix
(Thermo Fisher Scientiﬁc). PCR ampliﬁcation was performed on the Rotor-Gene
3000 (Corbett Research, Australia). Relative gene expression was normalized to
18S.
NF-κB luciferase reporter assay. RAW-ELAM macrophages were pre-treated
with COR123625 (50 µM) for 1 h prior to stimulation with LPS (100 ng ml−1) for
4 h. Cells were lysed in 50 μl 1× passive Lysis Reporter Buffer (Promega). Luciferase
activity was measured immediately after the addition of 30 μl of Luciferase Sub-
strate Solution (Luciferase Assay System, Promega) using the Inﬁnite M1000 Pro
plate-reader (Tecan, Australia).
Western blot. Cells were lysed in KalB lysis buffer (50 mM Tris, 150 mM NaCl, 1%
Trition X-100 and 1 mM EDTA, 1% NaF, 1% NaVO4, 1 mM PMSF, and protease
inhibitor cocktail, pH 7.4). Proteins from cell supernatants were extracted by
methanol–chloroform precipitation. Protein samples were resolved on 15%
NuPAGE® Bis-Tris gels (Novex, Thermo Fisher Scientiﬁc) and then transferred
onto PVDF membrane. Membranes were blocked in 5% (w/v) milk powder in Tris-
buffered saline with Tween-20 (TBS-T) (50 mM Tris-HCl, pH 7.6, 150 mM NaCl,
and 0.1% (v/v) Tween-20) for 1 h at room temperature. Membranes were incubated
with primary antibodies diluted in 5% (w/v) milk powder in TBS-T overnight at 4 °
C and then with horseradish peroxidise-conjugated secondary antibody diluted in
5% (w/v) milk powder in TBS-T for 1 h at room temperature. Membranes were
developed with Amersham ECL Western blotting detection reagents (GE Health-
care, Buckinghamshire, UK) and images either taken on ﬁlm or using a Fujiﬁlm
LAS-4000 luminescent reader. Primary antibodies used were mouse anti-caspase-1
(AG-20B-0042, Adipogen), rabbit anti-IL-1β (ab9722, Abcam), rabbit anti-NLRP3
(D4D8T, Cell Signaling Technology), rabbit anti-MIF (ab7207, Abcam), rabbit
anti-ASC (sc-22514-R, Santa Cruz), and mouse anti-vimentin (sc-373717, Santa
Cruz).
Co-immunoprecipitation. BMDM lysates were prepared as for Western blotting.
Lysates were then pre-cleared with 100 µl protein G sepahrose 4 fast ﬂow beads
(GE Healthcare) for 1 h at 4 °C. Beads were removed and lysates incubated with
selected antibodies overnight at 4 °C. Fifty microliters of bovine serum albumin-
blocked protein G separose beads were incubated with lysates for 2 h at 4 °C. Beads
were washed in KalB lysis buffer, then boiled in 30 µl of Laemelli sample buffer for
5 min at 95 °C, and ﬁnally analyzed by Western blotting. Antibodies used were as
for Western blot. In addition, normal rabbit IgG (sc-2027, Santa Cruz) was used for
controls.
Microscopy. For confocal and stimulated emission depletion (STED) super-
resolution microscopy, cells were cultured on glass coverslips and ﬁxed with either
ice-cold methanol for 5 min or 2% paraformaldehyde for 30 min. Before staining,
cells were permeabilized with 0.1% Triton X-100 and blocked with 0.5% teleostein
gelatin, 1% casein, and 5% goat serum in PBS. Cells were stained with primary
antibody in block buffer for 1 h at room temperature, followed by ﬂuorescently-
conjugated secondary antibodies in PBS for 1 h at room temperature. Nuclei were
stained with DAPI (4',6-diamidino-2-phenylindole; 1 μg ml−1, Sigma) for 5 min at
room temperature. Cells were mounted in ﬂuorescent mounting medium (Dako)
and imaged on an Olympus FV1200 confocal microscope. Images were analyzed
using the Imaris and Fiji imaging software.
For ASC-speck assays, either iBMDM stably expressing cerulean-ASC or
primary BMDM stained with rabbit anti-ASC (sc-22514-R, Santa Cruz) were
analyzed. Multiple z-sections were taken for each ﬁeld of view to ensure all specks
were recorded.
For FLIM-FRET, cells were cultured and stained as above. FLIM data was
recorded using an Olympus FV1000 microscope equipped with a PicoHarp300
FLIM extension and a 485 nm pulsed laser diode from PicoQuant. Pixel integration
time for FLIM images was kept at 40 μs per pixel and ﬂuorescence lifetime
histograms were accumulated to at least 10,000 counts in the maximum to ensure
sufﬁcient statistics for FLIM-FRET analysis. Photon count rates were kept at 5% of
the laser repetition rate to prevent pileup. FLIM-FRET analysis was performed
using the SymPhoTime 64 software (PicoQuant). Individual cells were chosen as
regions of interest (ROIs), then the ﬂuorescence lifetime decay of each ROI was
deconvolved with the measured instrument response function and ﬁtted with a
biexponential decay. The amplitude-weighted average lifetime was extracted from
each ﬁt and averaged over all values of one sample condition. Primary antibodies
used were as for Western blot (above), with the addition of biotinylated sheep anti-
MIF (detection antibody from MIF DuoSet ELISA, part number 843857, R&D
Systems). Secondary antibodies/reagents were anti-mouse-Alexa-Fluor 568, anti-
rabbit-Alexa-Fluor 488, and streptavidin-Alexa-Fluor 568 (Abcam).
Quantiﬁcation and statistical analyses. Data are presented as average values ±
SEM from multiple individual experiments/animals or as average values ± SD from
triplicate measurements in a representative experiment, as stated in ﬁgure legends.
Statistical analysis was carried out using one-way analysis of variance (ANOVA),
followed by Tukey's post hoc test, or paired Student’s t test, using the GraphPad
Prism software. P values <0.05 were considered signiﬁcant.
Data availability. Data are available from the authors upon request.
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